2015.05.14–
Contents
Holland J (ed.) (2001) Ecstasy - The Complete Guide - A Comprehensive Look at the Risks and Benefits of MDMA
Acknowledgments
About This Book
Introduction: Medicine for a New Millennium (Julie Holland, M.D.)
Part I: Let X = MDMA
• Introduction
01. The History of MDMA (Julie Holland, M.D.)
02. What Does MDMA Feel Like? (Gary Bravo, M.D.)
• Tolerance to the Subjective Effects of MDMA
• Spiritual Effects
• Conclusion
03. How MDMA Works in the Brain (Jessica Malberg, Ph.D., and Katherine R. Bonson, Ph.D.)
• How Neurotransmmiter Systems Function in the Brain
• MDMA and the 5-HT Transporter
• MDMA and Dopamine
• MDMA and 5-HT Receptors
• MDMA and Interactions with Other Drugs
• • Selective Serotonin Reuptake Inhibitors (SRIs)
• • Dextromethorphan (DXM)
• • MAO Inhibitors
• • Hallucinogens
• Summary
04. The Chemistry of MDMA (David Nichols, Ph.D.)
• Acids and Bases
05. MDMA Myths and Rumors Dispelled (Julie Holland, M.D.)
• Ecstasy Drains Your Spinal Fluid
• Ecstasy Causes Parkinson’s Disease
• A Single Dose of Ecstasy Causes Irreversible Brain Damage
• MDMA Was Initially Marketed as an Appetite Suppressant
• Ecstasy Is an Aphrodisiac
• Ecstasy Is a Date Rape Drug
• There Is Heroin in Ecstasy Pills
• Ecstasy Puts Holes in Your Brain
• Ecstasy Turns Your Brain into Cartilage
06. The Godparents of MDMA: An Interview with Ann and Sasha Shulgin (Julie Holland, M.D.)
Part II: Risks of MDMA Use
• Introduction
07. Medical Risks Associated with MDMA Use (John Henry, M.D., and Joe Rella, M.D.)
• Hyperthermia
• • Management of Ecstasy-Induced Hyperthermia
• Ecstasy-Induced Hyponatremia
• • Management of Ecstasy-Induced Hyponatremia
• The Serotonin Syndrome
• Cardiac Complications
• Liver Abnormalities
• The Liver Enzyme CYP2D6
• Neurological Complications
• General Management of MDMA Toxicity
• Assessing the Risk of MDMA Use
08. Mental Health Problems Associated with MDMA Use (Karl L. R. Jansen, M.D., Ph.D.)
• Problems with Reports of MDMA Use and Consequence
• • Was the Drug Taken Actually MDMA?
• • The Role of Polydrug Use
• • The Role of Set and Setting
• • The Probability of a Chance Association
• • Poor Pre-morbid Adjustment
• • Preexisting Neurochemical, Genetic, and Personality Differences
• • The Role of the Media
• What Are the Risks in Numerical Terms?
• Adverse Psychological Effects of MDMA
• • Psychosis
• • Anxiety Disorders and Panic Attacks
• • Depersonalization and Derealization
• • Depression and Mania
• • Cognitive Deficits (Impaired Memory, Attention, and Concentration)
• • The Pandora’s Box Syndrome
• • Flashbacks and Post-traumatic Stress Disorder
• • Sleep Disturbance
• Ecstasy—A Stepping-Stone to Other Drugs?
• Tolerance and Dependence
• Treatment
• • To Talk Down or to Medicate?
• • Psychotherapy
• • Medication
• • Meditation, Relaxation, Martial Arts, and Physical Exercise
• • Antioxidants and Food Supplements: Tryptophan and Tyrosin
• Conclusions
09. Does MDMA Cause Brain Damage? (Matthew Baggot and John Mendelson, M.D.)
• Introduction
• Long-Term Serotonergic Changes with MDMA
• • Serotonergic Changes Accompanied by Structural Changes to Axons
• • Serotonergic and Axonal Changes: Evidence of Damage?
• The Role of Oxidative Stress in MDMA Neurotoxicity
• • Proposed Sources of Oxidative Stress
• Dependence of the Extent of Neurotoxicity on Dose, Route of Administration, and Species
• • Reasons and Possible Justifications for High-Dose Administration of MDMA in Animals
• • Influence of Environment, Especially Ambient Temperature, on Neurotoxicity in Rats and Mice
• • Time Course of Changes and Extent of Recovery
• Behavioral and Functional Correlates of MDMA Exposure in Animals
• Studies Comparing Ecstasy Users and Nonusers
• • Personality Differences Between Ecstasy Users and Nonusers
• • Neurofunctional Differences Between Ecstasy Users and Nonusers
• • Cognitive Differences Between Ecstasy Users and Nonusers
• Possible Significance of Cognitive Differences and MDMA Neurotoxicity
• Findings in Prospective Clinical MDMA Studies
• • Potential Strategies for Reducing Risk of Neurotoxicity in Clinical Settings
• • The Need for More Research
• Summary
10. The Legal Status of MDMA around the World (Julie Holland, M.D.)
• The History of the Scheduling of MDMA
• Recent MDMA Legal Maneuvers
• • The Anti-Ecstasy Proliferation Act
• • The Methamphetamine and Club Drug Anti-Proliferation Act of 2000
• Penalties for Possession and Sale of MDMA in the United States
• • Examples of State Penalties
• • • California
• • • Delaware
• • • New Jersey
• • • Texas
• International Law Regarding MDMA
• • Australia
• • Brazil
• • Canada
• • China
• • Greece
• • Hong Kong
• • India
• • Israel
• • Italy
• • Singapore
• • Spain
• • Switzerland
• • United Kingdom
11. Minimizing Risks in the Dance Community: An Interview with Emanuel Sferios (Julie Holland, M.D.)
Part III: MDMA-assisted Psychotherapy
• Introduction
• MDMA acts as a catalyst to the psychotherapeutic process in four ways:
• • Connection
• • Recall
• • Insight
• • Acceptance
12. Using MDMA in Healing, Psychotherapy, and Spiritual Practice (Ralph Metzner, Ph.D., and Sophia Adamson)
• Guidelines for the Sacramental Use of Empathogenic Substances
• • Preparation and Set
• • Alchemical Catalysts
• • Setting and Context
• • Process and Method in Individual Sessions
• • Process and Ritual for Group Session
• • Follow-up and Aftereffects
13. Experience with the Interpersonal Psychedelics (Claudio Naranjo, M.D.)
• Introduction
• On Feeling Enhancement and the Facilitation of Psychotherapy
• MDA: The Drug of Analysis
• MMDA: The Eternal Now
• MDMA: A Nontoxic Alternative to MDA
14. Clinical Experience with MDMA-assisted Psychotherapy: An Interview with George Greer, M.D. (Julie Holland, M.D.)
Part IV: Potential Clinical Uses for MDMA
• Introduction
15. Using MDMA in the Treatment of Post-traumatic Stress Disorder (José Carlos Bouso)
• Introduction
• Post-traumatic Stress Disorder
• • Clinical Characteristics
• • Post-traumatic Stress Disorder in Victims of Sexual Assault
• • Treatment of Post-traumatic Stress Disorder in Victims of Sexual Assault
• MDMA and Post-traumatic Stress Disorder
• • Phase One
• • Phase Two
• • Phase Three
16. Using MDMA in the Treatment of Depression (June Riedlinger, R.Ph., Pharm. D., and Michael Montagne, Ph.D.)
• Introduction
• Extent and Nature of Depression
• Clinical Features of Depression
• Biochemical Basis of Depression
• Psychedelic Psychotherapy
• • Limitations of Psychedelic Psychotherapy
• • Psychedelic Therapy’s Relevance to MDMA Therapy
• MDMA’s Role in the Treatment of Depression
• • Treating Suicidal Depression with MDMA
• Risks of MDMA Use
• Conclusions
17. Using MDMA in the Treatment of Schizophrenia (Julie Holland, M.D.)
• The Dopamine Theory of Schizophrenia
• • Clinical Studies: Giving Dopamine Agonists to People with Schizophrenia
• • Serotonin and Schizophrenia
• • Clinical Studies: Giving Serotonin Agonists to Schizophrenics
• Pre-Pulse Inhibition
• Testimonials
• • Robert
• • John
• • James
18. Using MDMA in Alternative Medicine: An Interview with Andrew Weil, M.D. (Julie Holland, M.D.)
Part IV: MDMA Research
• Introduction
19. Clinical Research with MDMA: A Worldwide Review (Andrew Kleiman, M.D., and Julie Holland, M.D.)
• England
• Spain
• Switzerland
• United States
• Conclusion
20. Giving MDMA to Human Volunteers in Switzerland (Alex Gamma, Ph.D., Matthias E. Liechti, M.D., and Franz X. Vollenweider, M.D.)
• Introduction
• Psychological Effects of MDMA
• Cardiovascular Effects of MDMA
• Adverse Effects of MDMA
• Neurobiological Processes Associated with MDMA Effects
• • Effects of MDMA on Neurotransmitter Systems
• • Effects of MDMA on Brain Activity
• • Effects of MDMA on Information Processing
• Conclusion
21. Giving MDMA to Human Volunteers in the United States: An Interview with Charles Grob, M.D. (Julie Holland, M.D.)
Part V: MDMA and Society
• Introduction
• The Tribal Dance
• The Politics of Ecstasy
22. Ecstasy: Prescription for Cultural Renaissance (Douglas Rushkoff, Ph.D.)
23. MDMA and Spirituality: An Interview with Rabbi Zalman Schachter (Julie Holland, M.D.)
24. MDMA’s Promise as a Prescription Medicine: An Interview with Rick Doblin, Ph.D. (Julie Holland, M.D.)
Appendices
• History Timeline (Julie Holland, M.D.)
• Statistics Timeline (Julie Holland, M.D.)
• Table I: Studies of Long-term Behavioral or Functional Changes after MDMA in Animals (Matthew Baggot and John Mendelson, Ph.D.)
• Table II: Reported Neurofunctional Differences between Ecstasy Users and Nonusers (Matthew Baggot and John Mendelson, Ph.D.)
• Table III: Memory Studies of Ecstasy Users vs. Nonusers (Harry Sumnall)
References
Contributors
Index